Il y a eu 50 transactions d'initiés récentes enregistrées pour Athira Pharma, Inc. (ATHA), dont 35 achats et 14 ventes. Le total des achats d'initiés s'élève à $886.53K et le total des ventes d'initiés à $39.23K.
Les initiés notables ayant une activité récente comprennent Edelman Joseph, Fluke John M Jr, Johnson James A. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — ATHA
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2025-05-30 |
Edelman Joseph |
Director |
Attribution de RSU |
20,900 |
$0.31 |
$6.53K |
20,900 |
| 2025-05-30 |
Fluke John M Jr |
Director |
Attribution de RSU |
20,900 |
$0.31 |
$6.53K |
20,900 |
| 2025-05-30 |
Johnson James A |
Director |
Attribution de RSU |
20,900 |
$0.31 |
$6.53K |
20,900 |
| 2025-05-30 |
Pickering Grant |
Director |
Attribution de RSU |
20,900 |
$0.31 |
$6.53K |
20,900 |
| 2025-05-30 |
Panzara Michael A. |
Director |
Attribution de RSU |
20,900 |
$0.31 |
$6.53K |
20,900 |
| 2025-05-30 |
Romano Kelly A |
Director |
Attribution de RSU |
20,900 |
$0.31 |
$6.53K |
20,900 |
| 2025-05-30 |
Kosacz Barbara |
Director |
Attribution de RSU |
20,900 |
$0.31 |
$6.53K |
20,900 |
| 2025-03-03 |
Litton Mark James |
President and CEO |
Attribution de RSU |
222,543 |
- |
- |
222,543 |
| 2025-03-03 |
San Martin Javier |
Chief Medical Officer |
Attribution de RSU |
74,180 |
- |
- |
74,180 |
| 2025-03-03 |
Church Kevin |
Chief Scientific Officer |
Attribution de RSU |
58,563 |
- |
- |
58,563 |
| 2025-03-03 |
Worthington Mark |
General Counsel and Cco |
Attribution de RSU |
57,263 |
- |
- |
57,263 |
| 2025-03-03 |
Renninger Robert |
SVP, Finance and Accounting |
Attribution de RSU |
39,000 |
- |
- |
39,000 |
| 2025-01-02 |
Litton Mark James |
President and CEO |
Vente Informative |
25,107 |
$0.56 |
$14.11K |
242,591 |
| 2025-01-02 |
San Martin Javier |
Chief Medical Officer |
Vente Informative |
10,826 |
$0.56 |
$6.08K |
35,841 |
| 2025-01-02 |
Church Kevin |
Chief Scientific Officer |
Vente Informative |
8,510 |
$0.56 |
$4.78K |
130,761 |
| 2025-01-02 |
Worthington Mark |
General Counsel and Cco |
Vente Informative |
8,510 |
$0.56 |
$4.78K |
83,735 |
| 2025-01-02 |
Renninger Robert |
VP of Finance |
Vente Informative |
2,881 |
$0.56 |
$1.62K |
89,724 |
| 2024-12-31 |
Litton Mark James |
President and CEO |
Exercice d'Options (Vente) |
108,333 |
- |
- |
216,667 |
| 2024-12-31 |
San Martin Javier |
Chief Medical Officer |
Exercice d'Options |
46,667 |
- |
- |
46,667 |
| 2024-12-31 |
Church Kevin |
Chief Scientific Officer |
Exercice d'Options (Vente) |
36,667 |
- |
- |
73,333 |
| 2024-12-31 |
Worthington Mark |
General Counsel and Cco |
Exercice d'Options (Vente) |
36,667 |
- |
- |
73,333 |
| 2024-12-31 |
Renninger Robert |
VP of Finance |
Exercice d'Options (Vente) |
12,359 |
- |
- |
24,718 |
| 2024-11-18 |
Church Kevin |
Chief Scientific Officer |
Attribution de RSU |
9,920 |
$0.55 |
$5.46K |
102,604 |
| 2024-11-18 |
Worthington Mark |
General Counsel and Cco |
Attribution de RSU |
3,651 |
$0.55 |
$2.01K |
55,578 |
| 2024-11-18 |
Renninger Robert |
VP of Finance |
Attribution de RSU |
3,651 |
$0.55 |
$2.01K |
80,246 |
| 2024-10-03 |
Litton Mark James |
President and CEO |
Attribution de RSU |
325,000 |
$0.45 |
$146.22K |
325,000 |
| 2024-10-03 |
Litton Mark James |
President and CEO |
Attribution de RSU |
325,000 |
$0.43 |
$138.35K |
325,000 |
| 2024-10-01 |
San Martin Javier |
Chief Medical Officer |
Attribution de RSU |
140,000 |
- |
- |
140,000 |
| 2024-10-01 |
Church Kevin |
Chief Scientific Officer |
Attribution de RSU |
110,000 |
$0.45 |
$49.49K |
110,000 |
| 2024-10-01 |
Worthington Mark |
General Counsel and Cco |
Attribution de RSU |
110,000 |
$0.45 |
$49.49K |
110,000 |
| 2024-10-01 |
Renninger Robert |
VP of Finance |
Inconnu |
74,154 |
$3.26 |
$241.74K |
- |
| 2024-10-01 |
Renninger Robert |
VP of Finance |
Attribution de RSU |
37,077 |
$0.45 |
$16.68K |
37,077 |
| 2024-09-05 |
Gengos Andrew |
CFO and Chief Business Officer |
Vente Informative |
1,272 |
$0.57 |
$719.95 |
97,532 |
| 2024-09-05 |
Litton Mark James |
President and CEO |
Vente Informative |
5,032 |
$0.57 |
$2.85K |
159,365 |
| 2024-09-05 |
Church Kevin |
Chief Scientific Officer |
Vente Informative |
2,525 |
$0.57 |
$1.43K |
92,684 |
| 2024-09-05 |
Lenington Rachel |
COO and Cdo |
Vente Informative |
2,525 |
$0.57 |
$1.43K |
20,870 |
| 2024-09-05 |
Worthington Mark |
General Counsel |
Vente Informative |
2,525 |
$0.57 |
$1.43K |
51,927 |
| 2024-09-03 |
Gengos Andrew |
CFO and Chief Business Officer |
Attribution de RSU |
5,000 |
- |
- |
98,804 |
| 2024-09-03 |
Litton Mark James |
President and CEO |
Attribution de RSU |
20,000 |
- |
- |
164,397 |
| 2024-09-03 |
Church Kevin |
Chief Scientific Officer |
Attribution de RSU |
10,000 |
- |
- |
95,209 |
| 2024-09-03 |
Lenington Rachel |
COO and Cdo |
Attribution de RSU |
10,000 |
- |
- |
23,395 |
| 2024-09-03 |
Worthington Mark |
General Counsel |
Attribution de RSU |
10,000 |
- |
- |
54,452 |
| 2024-06-24 |
Romano Kelly A |
Director |
Achat Informatif |
27,400 |
$2.42 |
$66.18K |
80,715 |
| 2024-06-21 |
Romano Kelly A |
Director |
Achat Informatif |
15,000 |
$2.26 |
$33.87K |
53,315 |
| 2024-05-24 |
Edelman Joseph |
Director |
Attribution de RSU |
20,900 |
$2.64 |
$55.18K |
20,900 |
| 2024-05-24 |
Fluke John M Jr |
Director |
Attribution de RSU |
20,900 |
$2.64 |
$55.18K |
20,900 |
| 2024-05-24 |
Johnson James A |
Director |
Attribution de RSU |
20,900 |
$2.64 |
$55.18K |
20,900 |
| 2024-05-24 |
Pickering Grant |
Director |
Attribution de RSU |
20,900 |
$2.64 |
$55.18K |
20,900 |
| 2024-05-24 |
Panzara Michael A. |
Director |
Attribution de RSU |
20,900 |
$2.64 |
$55.18K |
20,900 |
| 2024-05-24 |
Romano Kelly A |
Director |
Attribution de RSU |
20,900 |
$2.64 |
$55.18K |
20,900 |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
